Predictors of Treatment Outcome in Intermittent Claudication
نویسندگان
چکیده
منابع مشابه
Predictors of treatment outcome in intermittent claudication.
OBJECTIVE To derive formulae to predict the likely 12-month health-related quality of life outcome following different treatments for intermittent claudication (IC). DESIGN A prospective, randomized, controlled study. MATERIALS One hundred and seventy-one unselected patients with stable IC were sequentially randomized to invasive therapy, supervised physical training or observation. Hierarc...
متن کاملFate in intermittent claudication: outcome and risk factors.
The fate of 257 consecutive patients (100 women) aged 36-85 years (mean 65) first seen with intermittent claudication in 1977 was analysed after a mean of 6.5 (SD 0.5) years. When first seen none of the patients complained of rest pain or had ulcers or gangrenous lesions on the feet. At follow up 113 of the patients (44%) had died. Causes of death were no different from those in the general pop...
متن کاملIntermittent claudication
Peripheral arterial disease is a common health problem that globally affects over 200 million individuals, and intermittent claudication (IC) is the most common symptomatic presentation. The leg symptoms in IC are provoked by walking exercise and can be alleviated by medical intervention, exercise training and invasive vascular interventions (revascularization). The quality of evidence for inva...
متن کاملinterspinous process implantation for the treatment of neurogenic intermittent claudication
results compared to pre-op scores, pf, ss, and vas scores for back, buttock and leg pain had a significant mean decrease at 6, 12, 24 months post-op (p < 0.05). based on the zcq and vas scores, a success rate of 79% (27.34), 78% (30.38) and 74% (17.23) were achieved at six months, 12 months, and 24 months respectively. conclusions x-stop is a safe and effective treatment for nic that provides m...
متن کاملCilostazol Has Beneficial Effects in Treatment of Intermittent Claudication
Background—Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator. This prospective, randomized, placebo-controlled, parallel-group clinical trial evaluated the efficacy of cilostazol for treatment of stable, moderately severe intermittent claudication. Methods and Results—Study inclusion criteria included age $40 year...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Vascular and Endovascular Surgery
سال: 2004
ISSN: 1078-5884
DOI: 10.1016/s1078-5884(03)00352-6